<DOC>
	<DOCNO>NCT00735072</DOCNO>
	<brief_summary>Many people HIV fail regain normal CD4 count despite effectively suppress HIV replication medication . Blocking `` co-receptor '' HIV might decrease inflammation immune system , potentially provide immune benefit . The goal current trial determine whether add maraviroc , new CCR5 `` co-receptor '' blocker , decrease inflammation , provide immune benefit patient low CD4 count despite undetectable viral load HIV medication . In study , HIV-infected patient receive antiretroviral therapy HIV receive either maraviroc placebo ( sugar pill ) day 24 week . After 24 week , study medication stop subject follow 12 week . Blood test measure extent inflammation , low-level viremia , immune function measure throughout trial compare treatment arm .</brief_summary>
	<brief_title>Maraviroc Immunomodulatory Drug Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure</brief_title>
	<detailed_description>Our primary hypothesis CCR5 inhibitor may protective immunomodulatory effect independent impact HIV replication . Specifically , predict maraviroc reduce persistent T cell activation prevents normal immune reconstitution HAART-mediated viral suppression . This hypothesis test context placebo control pilot study assess impact maraviroc antiretroviral-treated patient CD4+ T cell count le 350 cells/mm3 . In order address immunologic activity drug independent plasma HIV RNA level , study individual undetectable viral load ( &lt; 75 copy RNA/mL ) . Subjects randomize maraviroc 24 week match placebo 24 week , follow 12 week washout period . We use primary endpoint proportion CD8+ T cell co-expresses CD38 HLA-DR , outcomes well validated prior study . The primary outcome change percentage activate CD8+ T cell week 24 . Change CD4+ T cell count , HIV RNA level ( use ultra-sensitive technique ) , experimental immunologic measurement assess secondary outcome .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>1 . HIV1 infection , document licensed ELISA test kit confirm Western blot time prior study entry . HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test . 2 . Stable antiretroviral therapy least 12 month 3 . Screening CD4+ T cell count 350 cells/mm3 4 . All available CD4+ T cell count last year screen &lt; 350 cells/mm3 5 . Screening plasma HIV RNA level level detection ( &lt; 50 copy RNA/mL use Roche Amplicor &lt; 75 copies/mL use Bayer bDNA ) 6 . All available plasma HIV RNA level within past year level detection . Isolated value detectable &lt; 500 copy allow long plasma HIV RNA level time point undetectable . 7 . &gt; 90 % adherence therapy within precede 30 day , determine selfreport . 8 . Both male female subject eligible . Females childbearing potential must negative serum pregnancy test screen agree use doublebarrier method contraception throughout study period . 9 . Ability willingness subject legal guardian/representative provide inform consent 1 . Increase CD4 count &gt; 100 cells/mm3 past year . 2 . Patients intend modify antiretroviral therapy next 24 week reason . 3 . Serious illness require hospitalization parental antibiotic within precede 3 month . 4 . Concurrent treatment immunomodulatory drug , exposure immunomodulatory drug past 16 week . 5 . HBVsAg+ active hepatitis C hepatitis B require treatment subsequent 24 week . 6 . Prior exposure CCR5 inhibitor 7 . Screening absolute neutrophil count &lt; 1,000 cells/mm3 , platelet count &lt; 50,000 cells/mm3 , hemoglobin &lt; 8mg/dL , estimate creatinine clearance &lt; 40 mL/minute . 8 . Pregnant breastfeed woman 9 . Use Tenofovir Didanosine current antiretroviral therapy regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>T cell activation</keyword>
	<keyword>Antiretroviral Therapy</keyword>
	<keyword>CCR5</keyword>
	<keyword>Maraviroc</keyword>
</DOC>